198 related articles for article (PubMed ID: 30575329)
21. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
[TBL] [Abstract][Full Text] [Related]
22. Phase-Specific and Lifetime Costs of Multiple Myeloma Among Older Adults in the US.
Bhattacharya K; Bentley JP; Ramachandran S; Chang Y; Banahan BF; Shah R; Bhakta N; Yang Y
JAMA Netw Open; 2021 Jul; 4(7):e2116357. PubMed ID: 34241627
[TBL] [Abstract][Full Text] [Related]
23. Patient time costs associated with cancer care.
Yabroff KR; Davis WW; Lamont EB; Fahey A; Topor M; Brown ML; Warren JL
J Natl Cancer Inst; 2007 Jan; 99(1):14-23. PubMed ID: 17202109
[TBL] [Abstract][Full Text] [Related]
24. Estimating health care costs related to cancer treatment from SEER-Medicare data.
Brown ML; Riley GF; Schussler N; Etzioni R
Med Care; 2002 Aug; 40(8 Suppl):IV-104-17. PubMed ID: 12187175
[TBL] [Abstract][Full Text] [Related]
25. The value of medical interventions for lung cancer in the elderly: results from SEER-CMHSF.
Woodward RM; Brown ML; Stewart ST; Cronin KA; Cutler DM
Cancer; 2007 Dec; 110(11):2511-8. PubMed ID: 17955504
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare.
Ramsey SD; Howlader N; Etzioni RD; Donato B
J Clin Oncol; 2004 Dec; 22(24):4971-8. PubMed ID: 15611512
[TBL] [Abstract][Full Text] [Related]
27. National Utilization, Survival, and Costs Analysis of Treatment Options for Stage I Non-Small Cell Lung Cancer: A SEER-Medicare Database Analysis.
Mukherjee K; Davisson N; Malik S; Duszak R; Kokabi N
Acad Radiol; 2022 Feb; 29 Suppl 2():S173-S180. PubMed ID: 34404607
[TBL] [Abstract][Full Text] [Related]
28. Cancer-Attributable Medical Costs for Colorectal Cancer Patients by Phases of Care: What Is the Effect of a Prior Cancer History?
Mariotto AB; Warren JL; Zeruto C; Coughlan D; Barrett MJ; Zhao L; Yabroff KR
J Natl Cancer Inst Monogr; 2020 May; 2020(55):22-30. PubMed ID: 32412066
[TBL] [Abstract][Full Text] [Related]
29. Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.
Shih YT; Xu Y; Chien CR; Kim B; Shen Y; Li L; Geynisman DM
Pharmacoeconomics; 2019 Dec; 37(12):1495-1507. PubMed ID: 31286464
[TBL] [Abstract][Full Text] [Related]
30. Racial/ethnic disparities in colorectal cancer treatment utilization and phase-specific costs, 2000-2014.
Tramontano AC; Chen Y; Watson TR; Eckel A; Hur C; Kong CY
PLoS One; 2020; 15(4):e0231599. PubMed ID: 32287320
[TBL] [Abstract][Full Text] [Related]
31. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
[TBL] [Abstract][Full Text] [Related]
32. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
Aly A; Johnson C; Yang S; Botteman MF; Rao S; Hussain A
J Med Econ; 2019 Jul; 22(7):662-670. PubMed ID: 30836812
[No Abstract] [Full Text] [Related]
33. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
34. Phase-specific healthcare costs of cervical cancer: estimates from a population-based study.
Liu N; Mittmann N; Coyte PC; Hancock-Howard R; Seung SJ; Earle CC
Am J Obstet Gynecol; 2016 May; 214(5):615.e1-615.e11. PubMed ID: 26627729
[TBL] [Abstract][Full Text] [Related]
35. Costs of Cancer Care Across the Disease Continuum.
Kaye DR; Min HS; Herrel LA; Dupree JM; Ellimoottil C; Miller DC
Oncologist; 2018 Jul; 23(7):798-805. PubMed ID: 29567821
[TBL] [Abstract][Full Text] [Related]
36. Racial and geographic disparities in the patterns of care and costs at the end of life for patients with lung cancer in 2007-2010 after the 2006 introduction of bevacizumab.
Du XL; Parikh RC; Lairson DR
Lung Cancer; 2015 Dec; 90(3):442-50. PubMed ID: 26439736
[TBL] [Abstract][Full Text] [Related]
37. Redistribution of health care costs after the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2005.
Dinan MA; Curtis LH; Carpenter WR; Biddle AK; Abernethy AP; Patz EF; Schulman KA; Weinberger M
J Thorac Oncol; 2014 Apr; 9(4):512-8. PubMed ID: 24736074
[TBL] [Abstract][Full Text] [Related]
38. Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.
Vyas A; Madhavan SS; Sambamoorthi U; Pan XL; Regier M; Hazard H; Kalidindi S
J Natl Compr Canc Netw; 2017 Nov; 15(11):1401-1409. PubMed ID: 29118232
[No Abstract] [Full Text] [Related]
39. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis.
Riley GF; Potosky AL; Lubitz JD; Kessler LG
Med Care; 1995 Aug; 33(8):828-41. PubMed ID: 7637404
[TBL] [Abstract][Full Text] [Related]
40. Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA.
Steuten L; Garmo V; Phatak H; Sullivan SD; Nghiem P; Ramsey SD
Appl Health Econ Health Policy; 2019 Oct; 17(5):733-740. PubMed ID: 31250217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
